Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance.

Abstract

The optimal management of the small number of patients who experience early failure of eBEACOPP in Hodgkin lymphoma (HL) is unclear. We identified 12 patients with HL who progressed within 12 months of the front-line therapy between January 2010 and July 2019. Median time of first progression following diagnosis was 7 months (range 2.1-13.2). Nine patients proceeded to stem cell therapy following salvage therapy (8 autografts, 1 allograft). Seven patients received novel therapy after relapse, of these, 6 were alive at census, versus 2 out of 5 of those who had standard therapy alone. At the end of follow up (median 22 months), 4 were deceased from progressive disease, 6 were in complete remission and 2 in partial remission on continuing therapy. The outcome of patients with primary refractory HL to eBEACOPP therapy is better than expected and the use of a novel agents after relapse may be a contributing factor.

• Authors: Matthew Harwood, Georgina Hodges, Xuan Tan, Chan Y Cheah, Kenneth Lim, Matthew Ku, Constantine Tam, Ingemar Lagerlof, Tara Cochrane
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 61 Issue 14 Pg. 3412-3416 (12 2020) ISSN: 1029-2403 [Electronic] United States
• PMID: 32856509 (Publication Type: Journal Article)

Chemical References

• Vincristine
• Etoposide
• Cyclophosphamide

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cyclophosphamide (therapeutic use)
• Etoposide (therapeutic use)
• Hodgkin Disease (drug therapy)
• Humans
• Neoplasm Recurrence, Local (drug therapy)
• Recurrence
• Salvage Therapy
• Treatment Outcome
• Vincristine (therapeutic use)